Flexion Therapeutics (Flexion Therapeutics) Accounts Receivable : $29.4 Mil (As of Sep. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Flexion Therapeutics's accounts receivables for the quarter that ended in Sep. 2021 was $29.4 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Flexion Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2021 was 125.69.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Flexion Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2021 was $-2.56.

Flexion Therapeutics Accounts Receivable Historical Data

The historical data trend for Flexion Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics Accounts Receivable Chart

Flexion Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Accounts Receivable

Get a 7-Day Free Trial

0.41

13.12

37.12

30.03

Flexion Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Accounts Receivable	Get a 7-Day Free Trial															27.90	30.03	30.37	35.10	29.38

Flexion Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Flexion Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Flexion Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	29.375	/	21.326	*	91
=	125.69

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Flexion Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Flexion Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2021 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(142.053	+	0.75 * 29.375	+	0.5 * 14.669	-	300.308
-	0	-	0)	/	50.3204
=	-2.56

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Flexion Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Flexion Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Flexion Therapeutics (Flexion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Mall Road, Suite 301, Burlington, MA, USA, 01803

Website

http://www.flexiontherapeutics.com

Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.

Executives

Mark S. Levine	officer: General Counsel	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth	officer: Chief Regulatory Officer	AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth	officer: Chief Strategy Officer	C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz	officer: Chief Financial Officer	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman	officer: Chief Commercial Officer	C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley	officer: Chief Medical Officer	C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman	director, officer: President and CEO	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo	director	C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield	director
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy	director	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403